LKFT
Income statement / Annual
Last year (2025), Lakefront Biotherapeutics NV's total revenue was $1.11 B,
an increase of 303.50% from the previous year.
In 2025, Lakefront Biotherapeutics NV's net income was $320.88 M.
See Lakefront Biotherapeutics NV,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$1.11 B |
$275.65 M |
$239.72 M |
$241.25 M |
$234.38 M |
| Cost of Revenue |
$29.74 M
|
$34.86 M
|
$0.00
|
$0.00
|
$320.50 M
|
| Gross Profit |
$1.08 B
|
$240.79 M
|
$239.72 M
|
$241.25 M
|
-$86.12 M
|
| Gross Profit Ratio |
0.97
|
0.87
|
1
|
1
|
-0.37
|
| Research and Development Expenses |
$459.42 M
|
$335.46 M
|
$241.29 M
|
$269.80 M
|
$320.50 M
|
| General & Administrative Expenses |
$110.57 M
|
$94.07 M
|
$92.48 M
|
$102.04 M
|
$127.74 M
|
| Selling & Marketing Expenses |
$1.39 M
|
$2.81 M
|
$1.78 M
|
$1.27 M
|
$3.78 M
|
| Selling, General & Administrative Expenses |
$111.96 M
|
$96.88 M
|
$94.25 M
|
$103.31 M
|
$131.52 M
|
| Other Expenses |
$9.74 M
|
-$3.22 M
|
-$7.56 M
|
-$801.00 K
|
-$366.57 M
|
| Operating Expenses |
$581.12 M
|
$429.12 M
|
$327.99 M
|
$372.31 M
|
$85.45 M
|
| Cost And Expenses |
$610.86 M
|
$463.99 M
|
$327.99 M
|
$372.31 M
|
$405.95 M
|
| Interest Income |
$46.34 M
|
$89.77 M
|
$79.61 M
|
$18.09 M
|
$0.00
|
| Interest Expense |
$2.22 M
|
$911.00 K
|
$1.77 M
|
$9.16 M
|
$8.73 M
|
| Depreciation & Amortization |
$55.88 M
|
$45.50 M
|
$43.64 M
|
$65.57 M
|
$8.31 M
|
| EBITDA |
$358.96 M |
$43.33 M |
$51.04 M |
$3.87 M |
-$163.26 M |
| EBITDA Ratio |
0.32
|
0.16
|
0.21
|
0.02
|
-0.7
|
| Operating Income Ratio |
0.45
|
-0.68
|
-0.37
|
-0.54
|
-0.73
|
| Total Other Income/Expenses Net |
-$200.52 M
|
$185.25 M
|
$93.89 M
|
$60.21 M
|
$52.17 M
|
| Income Before Tax |
$300.87 M
|
-$3.09 M
|
$5.63 M
|
-$70.85 M
|
-$119.40 M
|
| Income Before Tax Ratio |
0.27
|
-0.01
|
0.02
|
-0.29
|
-0.51
|
| Income Tax Expense |
-$18.62 M
|
-$1.80 M
|
$9.61 M
|
$572.00 K
|
$1.39 M
|
| Net Income |
$320.88 M
|
$74.08 M
|
$211.70 M
|
-$217.99 M
|
-$103.23 M
|
| Net Income Ratio |
0.29
|
0.27
|
0.88
|
-0.9
|
-0.44
|
| EPS |
4.87 |
1.12 |
3.21 |
-3.32 |
-1.84 |
| EPS Diluted |
4.87 |
1.12 |
3.21 |
-3.32 |
-1.84 |
| Weighted Average Shares Out |
$65.90 M
|
$66.14 M
|
$65.88 M
|
$65.66 M
|
$55.98 M
|
| Weighted Average Shares Out Diluted |
$65.90 M
|
$66.14 M
|
$65.88 M
|
$65.66 M
|
$65.50 M
|
| Link |
|
|
|
|
|
